Related references
Note: Only part of the references are listed.Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population
Marjan Kerkhof et al.
THORAX (2018)
Asthma referrals: a key component of asthma management that needs to be addressed
David Price et al.
JOURNAL OF ASTHMA AND ALLERGY (2017)
Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations
Loren C. Denlinger et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma
Christopher E. Brightling et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria
M. Hew et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2016)
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study
Njira Lugogo et al.
CLINICAL THERAPEUTICS (2016)
Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry
P. G. Gibson et al.
INTERNAL MEDICINE JOURNAL (2016)
A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan
Hae-Sim Park et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2016)
Factors affecting ability to achieve asthma control in adult patients with moderate to severe persistent asthma
Lyne Scott et al.
JOURNAL OF ASTHMA (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
Sally Wenzel et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Effects of older age and age of asthma onset on clinical and inflammatory variables in severe refractory asthma
Rekha Chaudhuri et al.
RESPIRATORY MEDICINE (2016)
Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status
Huib A. M. Kerstjens et al.
RESPIRATORY MEDICINE (2016)
Profile of difficult to treat asthma patients referred for systematic assessment
N. Radhakrishna et al.
RESPIRATORY MEDICINE (2016)
Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study
Jing Li et al.
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH (2016)
Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)
Robert M. Niven et al.
BMJ OPEN (2016)
Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma
Nestor A. Molfino et al.
BMJ OPEN (2016)
Asthma-related deaths
Gennaro D'Amato et al.
MULTIDISCIPLINARY RESPIRATORY MEDICINE (2016)
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial
Paul M. O'Byrne et al.
LANCET RESPIRATORY MEDICINE (2016)
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
Nicola A. Hanania et al.
LANCET RESPIRATORY MEDICINE (2016)
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
Hector G. Ortega et al.
LANCET RESPIRATORY MEDICINE (2016)
Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting
Robert S. Zeiger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2016)
Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting
Benjamin Chastek et al.
Journal of Managed Care & Specialty Pharmacy (2016)
Tiotropium may improve asthma symptoms and lung function in asthmatic patients with irreversible airway obstruction: the real-life data
Oznur Abadoglu et al.
CLINICAL RESPIRATORY JOURNAL (2016)
Comparison of allergic asthma patients treated with omalizumab and non-allergic patients treated with continuous oral corticosteroids: results of five year follow-up therapies
Bilun Gemicioglu et al.
TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX (2016)
X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients
Jens Schreiber et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Real life study of three years omalizumab in patients with difficult-to-control asthma
J. Jesus Lopez Tiro et al.
ALLERGOLOGIA ET IMMUNOPATHOLOGIA (2015)
Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results
James L. Zazzali et al.
ALLERGY AND ASTHMA PROCEEDINGS (2015)
Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma
Susan L. Janson et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2015)
Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma
Patrick W. Sullivan et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2015)
Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort
Dominick E. Shaw et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Acute and chronic systemic corticosteroid-related complications in patients with severe asthma
Patrick Lefebvre et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
The prevalence of severe refractory asthma
Pieter-Paul W. Hekking et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation
Patrick W. Sullivan et al.
JOURNAL OF ASTHMA (2015)
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy
Federica Novelli et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2015)
Influence of upper airway abnormalities on the control of severe asthma: a cross-sectional study
Francisco Soares Nascimento-Sampaio et al.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2015)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
David B. Price et al.
LANCET RESPIRATORY MEDICINE (2015)
The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry
Stephen O'Neill et al.
THORAX (2015)
Effectiveness of vitamin D3 in severe persistent asthmatic patients: A double blind, randomized, clinical study
Muhasaparur Ganesan Rajanandh et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2015)
National and regional asthma programmes in Europe
Olof Selroos et al.
EUROPEAN RESPIRATORY REVIEW (2015)
Profile of patients treated with omalizumab in routine clinical practice in Spain
J. Ancochea et al.
ALLERGOLOGIA ET IMMUNOPATHOLOGIA (2014)
Budesonide/formoterol maintenance and reliever therapy in moderate-to-severe asthma: Effects on eosinophilic airway inflammation
Kiyoshi Takeyama et al.
ALLERGY AND ASTHMA PROCEEDINGS (2014)
Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study
Tomoko Tajiri et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2014)
Factors associated with severe uncontrolled asthma and the perception of control by physicians and patients
Maria del Carmen Vennera et al.
ARCHIVOS DE BRONCONEUMOLOGIA (2014)
Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma
Laura Somerville et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Risk factors for death in patients with severe asthma
Andreia Guedes Oliva Fernandes et al.
JORNAL BRASILEIRO DE PNEUMOLOGIA (2014)
Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: A randomized trial
Erika H. De Boever et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Continuous terbutaline infusion in severe asthma in adults: a retrospective study of long-term efficacy and safety
Adel H. Mansur et al.
JOURNAL OF ASTHMA (2014)
Health status measurement in patients with severe asthma
Jeannette B. Peters et al.
RESPIRATORY MEDICINE (2014)
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control
M. Molimard et al.
RESPIRATORY MEDICINE (2014)
Clinical experience with omalizumab in a Portuguese severe asthma unit
S. Alfarroba et al.
REVISTA PORTUGUESA DE PNEUMOLOGIA (2014)
Omalizumab management beyond clinical trials: The added value of a network model
Marco Caminati et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2014)
Budget Impact Analysis Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
Sean D. Sullivan et al.
VALUE IN HEALTH (2014)
IMPACT OF OMALIZUMAB ON ALL-CAUSE AND ASTHMA-RELATED HEALTH CARE RESOURCE UTILISATION IN PATIENTS WITH MODERATE OR SEVERE PERSISTENT ASTHMA
S. J. Turner et al.
VALUE IN HEALTH (2014)
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2014)
Asthma Exacerbation Rates in Adults Are Unchanged Over a 5-Year Period Despite High-Intensity Therapy
Michael Schatz et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2014)
The Prevalence of Severe Asthma and Low Asthma Control Among Danish Adults
Anna von Bulow et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2014)
Clinical Burden and Predictors of Asthma Exacerbations in Patients on Guideline-based Steps 4-6 Asthma Therapy in the TENOR Cohort
William J. Calhoun et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2014)
Does Omalizumab Make a Difference to the Real-life Treatment of Asthma Exacerbations? Results From a Large Cohort of Patients With Severe Uncontrolled Asthma
Lamiae Grimaldi-Bensouda et al.
CHEST (2013)
A Proof-of-Concept, Randomized, Controlled Trial of Omalizumab in Patients With Severe, Difficult-to-Control, Nonatopic Asthma
Gilles Garcia et al.
CHEST (2013)
The Effect of Omalizumab in Treatment of Inadequate Controlled Severe Persistent Asthma Patient
Mohamed Zakaria et al.
CHEST (2013)
Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation
G. Norman et al.
HEALTH TECHNOLOGY ASSESSMENT (2013)
Severe adult-onset asthma: A distinct phenotype
Marijke Amelink et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Assessment of Long-term Omalizumab Treatment in Patients with Severe Allergic Asthma Long-term Omalizumab Treatment in Severe Asthma
Eylem Sercan Ozgur et al.
JOURNAL OF ASTHMA (2013)
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Sally Wenzel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Natural history and risk factors of obstructive changes over a 10-year period in severe asthma
Kazuto Matsunaga et al.
RESPIRATORY MEDICINE (2013)
Phenotypic predictors of response to oral glucocorticosteroids in severe asthma
Maciej Kupczyk et al.
RESPIRATORY MEDICINE (2013)
A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland
A. Subramaniam et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2013)
Oestrogen induces mucoid conversion of Pseudomonas Aeruginosa in women with cystic fibrosis, and increases exacerbations
Gemma Hayes
THORAX (2013)
Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial
Guy G. Brusselle et al.
THORAX (2013)
ESTIMATING THE BUDGET IMPACT OF ADDING OMALIZUMAB TO STANDARD THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ALLERGIC ASTHMA FROM PRIVATE HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL
C. Suzuki et al.
VALUE IN HEALTH (2013)
Predictors for Identifying the Efficacy of Systemic Steroids on Sustained Exhaled Nitric Oxide Elevation in Severe Asthma
Kazuto Matsunaga et al.
ALLERGOLOGY INTERNATIONAL (2013)
Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma
Marie-Helene Lafeuille et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2012)
Omalizumab in patients with severe asthma: the XCLUSIVE study
Christian Schumann et al.
CLINICAL RESPIRATORY JOURNAL (2012)
Airway impedance entropy and exacerbations in severe asthma
Sherif Gonem et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Comparison between two methods of asthma control evaluation based on individual perception
Paula Cristina Andrade Almeida et al.
JORNAL BRASILEIRO DE PNEUMOLOGIA (2012)
Specific IgE against Staphylococcus aureus enterotoxins: An independent risk factor for asthma
Claus Bachert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Economic Costs for Adult Asthmatics According to Severity and Control Status in Korean Tertiary Hospitals
Sae-Hoon Kim et al.
JOURNAL OF ASTHMA (2012)
Omalizumab Reduces Corticosteroid Use in Patients with Severe Allergic Asthma: Real-Life Experience in Israel
Menachem Rottem
JOURNAL OF ASTHMA (2012)
Effect of Omalizumab as Add-On Therapy on Asthma-Related Quality of Life in Severe Allergic Asthma: A Brazilian Study (QUALITX)
A. S. Rubin et al.
JOURNAL OF ASTHMA (2012)
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Omalizumab on Asthma Control in Patients with Persistent Allergic Asthma
Jose Bardelas et al.
JOURNAL OF ASTHMA (2012)
Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry-Some New Approaches
Maria del Carmen Vennera et al.
JOURNAL OF ASTHMA (2012)
A 36-Month Study on the Cost/Utility of Add-On Omalizumab in Persistent Difficult-to-Treat Atopic Asthma in Italy
Roberto Walter Dal Negro et al.
JOURNAL OF ASTHMA (2012)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy
Huib A. M. Kerstjens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma
Makoto Hoshino et al.
RESPIRATION (2012)
Monitoring free serum IgE in severe asthma patients treated with omalizumab
Stephanie Korn et al.
RESPIRATORY MEDICINE (2012)
Clinical characteristics and possible phenotypes of an adult severe asthma population
Regina Maria de Carvalho-Pinto et al.
RESPIRATORY MEDICINE (2012)
Real-life prospective study on asthma control in Italy: Cross-sectional phase results
Luigi Allegra et al.
RESPIRATORY MEDICINE (2012)
Role of neutrophils in persistent airway obstruction due to refractory asthma
Jae-Sung Choi et al.
RESPIROLOGY (2012)
Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean real-life experience
Eleni G. Tzortzaki et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2012)
Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands
Floortje van Nooten et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
J. Bousquet et al.
ALLERGY (2011)
Reslizumab for Poorly Controlled, Eosinophilic Asthma A Randomized, Placebo-controlled Study
Mario Castro et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria
Stephanie Korn et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2011)
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy A Randomized Trial
Nicola A. Hanania et al.
ANNALS OF INTERNAL MEDICINE (2011)
Persistence of Community-Acquired Respiratory Distress Syndrome Toxin-Producing Mycoplasma pneumoniae in Refractory Asthma
Jay Peters et al.
CHEST (2011)
Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial
Huib A. M. Kerstjens et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Concomitant Asthma Medication Use in Patients Receiving Omalizumab: Results from Three Large Insurance Claims Databases
Marie-Helene Lafeuille et al.
JOURNAL OF ASTHMA (2011)
Changes in Total IgE Plasma Concentration Measured at the Third Month during Anti-IgE Treatment Predict Future Exacerbation Rates in Difficult-to-Treat Atopic Asthma: A Pilot Study
Roberto W. Dal Negro et al.
JOURNAL OF ASTHMA (2011)
A study of a multi-level intervention to improve non-adherence in difficult to control asthma
Jacqueline Gamble et al.
RESPIRATORY MEDICINE (2011)
Internet-based tapering of oral corticosteroids in severe asthma: a pragmatic randomised controlled trial
Simone Hashimoto et al.
THORAX (2011)
IMPROVEMENT OF QUALITY OF LIFE IN PATIENTS WITH CONCOMITANT ALLERGIC ASTHMA AND ATOPIC DERMATITIS: ONE YEAR FOLLOW-UP OF OMALIZUMAB THERAPY
P. Velling et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2011)
Care of asthma patients in relation to guidelines
Michael S. Broder et al.
ALLERGY AND ASTHMA PROCEEDINGS (2010)
Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma
Federico L. Dente et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2010)
Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma
Stephanie Korn et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2010)
Health experiences of adolescents with uncontrolled severe asthma
Kate Edgecombe et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2010)
Relationship Between Comorbidity and Asthma Control
Luis Alejandro Perez De Llano et al.
ARCHIVOS DE BRONCONEUMOLOGIA (2010)
Direct health care costs associated with asthma in British Columbia
Mohsen Sadatsafavi et al.
CANADIAN RESPIRATORY JOURNAL (2010)
Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma
L. A. Perez-de-Llano et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Insights into severe asthma control as assessed by guidelines, pulmonologist, patient, and partner
Mathieu Molimard et al.
JOURNAL OF ASTHMA (2010)
Factors Associated With the Control of Severe Asthma
Juan Luis Rodriguez Hermosa et al.
JOURNAL OF ASTHMA (2010)
Italian real-life experience of omalizumab
M. Cazzola et al.
RESPIRATORY MEDICINE (2010)
Omalizumab-induced decrease of FcεRI expression in patients with severe allergic asthma
Pascal Chanez et al.
RESPIRATORY MEDICINE (2010)
Phenotype of asthmatic patients according to a score derived from the Asthma Control Test®
P. Godard et al.
REVUE DES MALADIES RESPIRATOIRES (2010)
Increased levels of osteopontin in sputum supernatant in severe refractory asthma
Vasiliki Delimpoura et al.
THORAX (2010)
Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics
M. Humbert et al.
ALLERGY (2009)
Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis
M. Humbert et al.
ALLERGY (2009)
A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma
Sally E. Wenzel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
The Prevalence of Nonadherence in Difficult Asthma
Jacqueline Gamble et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Factors associated with uncontrolled asthma in Porto Alegre, Brazil
P. T. R. Dalcin et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2009)
Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma
Joanne Y. Julien et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Phenotypic determinants of uncontrolled asthma
Valerie Siroux et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany
S. Korn et al.
RESPIRATORY MEDICINE (2009)
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
G. Brusselle et al.
RESPIRATORY MEDICINE (2009)
High-sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthma
Ziemowit Zietkowski et al.
RESPIRATORY MEDICINE (2009)
The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use
Stephanie C. Manson et al.
RESPIRATORY MEDICINE (2009)
Economic burden of asthma: a systematic review
Katayoun Bahadori et al.
BMC Pulmonary Medicine (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
The impact of GINA suggested drugs for the treatment of asthma on Health-Related Quality of Life:: a GA2LEN review
I. Baiardini et al.
ALLERGY (2008)
A breath for health: an exploratory study in severe asthma patients in Turkey
S. Bavbek et al.
ALLERGY (2008)
Airway inflammation in obese and nonobese patients with difficult-to-treat asthma
I. H. van Veen et al.
ALLERGY (2008)
Symptoms, spirometry, exhaled nitric oxide, and asthma exacerbations in clinical practice
Daniel Menzies et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2008)
Insurance status and asthma-related health care utilization in patients with severe asthma
Anju T. Peters et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2008)
Extent of uncontrolled disease and associated medical costs in severe asthma - a PHARMO study
Nancy S. Breekveldt-Postma et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Effectiveness of omalizumab (Xolair (R)) in the first patients treated in real-life practice in France
Mathieu Molimard et al.
RESPIRATORY MEDICINE (2008)
Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label study
R. Niven et al.
RESPIRATORY MEDICINE (2008)
The role of a soluble TNFα receptor fusion protein (etanercept) in corticosteroid refractory asthma:: a double blind, randomised, placebo controlled trial
J. B. Morjaria et al.
THORAX (2008)
National asthma education and prevention program - Expert panel report 3 (EPR-3): Guidelines for the diagnosis and management of asthma - Summary report 2007
[Anonymous]
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma
Jill P. Karpel et al.
RESPIRATORY MEDICINE (2007)
The correlation between asthma control and health status: the GOAL study
E. D. Bateman et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline
Hiromasa Inoue et al.
RESPIRATION (2007)
Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment
Stephen P. Peters et al.
RESPIRATORY MEDICINE (2006)
Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma
Eric Bateman et al.
CHEST (2006)
Effects of nebulized sodium cromoglycate on adult patients with severe refractory asthma
Y Sano et al.
RESPIRATORY MEDICINE (2006)
Profiles of proinflammatory cytokines in sputum from different groups of severe asthmatic patients
Federico L. Dente et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2006)
Risk factors of frequent exacerbations in difficult-to-treat asthma
A ten Brinke et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire
M Gaga et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2005)
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment):: INNOVATE
M Humbert et al.
ALLERGY (2005)
Relationship between lung function and asthma symptoms in patients with difficult to control asthma
S Aburuz et al.
JOURNAL OF ASTHMA (2005)
Parameters associated with persistent airflow obstruction in chronic severe asthma
D Bumbacea et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation
C Miranda et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Development of the asthma control test: A survey for assessing asthma control
RA Nathan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
The position of pranlukast, a cysteinyl leukotriene receptor antagonist, in the long-term treatment of asthma - 5-year follow-up study
Y Obase et al.
RESPIRATION (2004)
Share Paper
